Aminoglycosides in Septic Shock View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-03-19

AUTHORS

Alexandre Boyer, Didier Gruson, Stéphane Bouchet, Benjamin Clouzeau, Bui Hoang-Nam, Frédéric Vargas, Hilbert Gilles, Mathieu Molimard, Anne-Marie Rogues, Nicholas Moore

ABSTRACT

Aminoglycoside nephrotoxicity has been reported in patients with sepsis, and several risk factors have been described. Once-daily dosing and shorter treatment have reduced nephrotoxicity risk, and simplified aminoglycoside monitoring. This review focuses on nephrotoxicity associated with aminoglycosides in the subset of patients with septic shock or severe sepsis. These patients are radically different from those with less severe sepsis. They may have, for instance, renal impairment due to the shock per se, sepsis-related acute kidney injury, frequent association with pre-existing risk factors for renal failure such as diabetes, dehydration and other nephrotoxic treatments. In this category of patients, these risk factors might modify substantially the benefit-risk ratio of aminoglycosides. In addition, aminoglycoside administration in critically ill patients with sepsis is complicated by an extreme inter- and intra-individual variability in drug pharmacokinetic/pharmacodynamic characteristics: the volume of distribution (Vd) is frequently increased while the elimination constant can be either increased or decreased. Consequently, and although its effect on nephrotoxicity has not been explored, a different administration schedule, i.e. a high-dose once daily (HDOD), and several therapeutic drug monitoring (TDM) options have been proposed in these patients. This review describes the historical perspective of these different options, including those applying to subsets of patients in which aminoglycoside administration is even more complex (obese intensive care unit [ICU] patients, patients needing continuous or discontinuous renal replacement therapy [CRRT/DRRT]). A simple linear dose adjustment according to aminoglycoside serum concentration can be classified as low-intensity TDM. Nomograms have also been proposed, based on the maximum (peak) plasma concentration (Cmax) objectives, weight and creatinine clearance. The Sawchuk and Zaske method (based on the determination of Cmax and an intermediate aminoglycoside assay before minimum plasma concentration) and the Bayesian method were both classified as high-intensity TDM programmes. Given the mean cost of aminoglycoside nephrotoxicity, these programmes may be cost-effective if its prevalence is above 10 %. However, none of these high-intensity TDM programmes have demonstrated a reduction of aminoglycoside-associated nephrotoxicity in patients with septic shock. Therefore, the questions remain as to, first, whether a TDM programme is relevant and, second, what intensity of TDM is achievable in the ICU, i.e. how it can be practically applied in the ICU setting where urgent care and high workload are substantial obstacles to a sophisticated, optimized aminoglycoside administration. More... »

PAGES

217-230

References to SciGraph publications

  • 1996-11. The Economic Impact of Once-Daily versus Conventional Administration of Gentamicin and Tobramycin in PHARMACOECONOMICS
  • 1990-05. Gentamicin volume of distribution in critically ill septic patients in INTENSIVE CARE MEDICINE
  • 2009-06-23. Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database in INTENSIVE CARE MEDICINE
  • 1998-11. Risk Factors for Toxicity in Elderly Patients Given Aminoglycosides Once Daily in JOURNAL OF GENERAL INTERNAL MEDICINE
  • 2003-04. Aminoglycoside Dosages and Nephrotoxicity in CLINICAL PHARMACOKINETICS
  • 2004-05-24. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group in CRITICAL CARE
  • 2002-05-30. Experience with a once-daily dosing program of aminoglycosides in critically ill patients in INTENSIVE CARE MEDICINE
  • 2001-07-01. Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis in THE AMERICAN JOURNAL OF GASTROENTEROLOGY
  • 1997-07. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 1976-04. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 2009-09-15. Evaluation of “Loss” and “End stage renal disease” after acute kidney injury defined by the Risk, Injury, Failure, Loss and ESRD classification in critically ill patients in INTENSIVE CARE MEDICINE
  • 2000-04. A Concept for Pharmacokinetic-Pharmacodynamic Dosage Adjustment in Renal Impairment in CLINICAL PHARMACOKINETICS
  • 1997-03. Drug Administration in Patients with Renal Insufficiency in DRUG SAFETY
  • 1998-10. Economic Impact of Aminoglycoside Toxicity and its Prevention Through Therapeutic Drug Monitoring in PHARMACOECONOMICS
  • 1977-12. Gentamicin disposition and tissue accumulation on multiple dosing in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 1989-06. A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients in INTENSIVE CARE MEDICINE
  • 1996-05. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient in INTENSIVE CARE MEDICINE
  • 2001-11. Individualising Aminoglycoside Dosage Regimens after Therapeutic Drug Monitoring in CLINICAL PHARMACOKINETICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s40264-013-0031-0

    DOI

    http://dx.doi.org/10.1007/s40264-013-0031-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1010536097

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/23508544


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aminoglycosides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anti-Bacterial Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Monitoring", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Kidney", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Renal Insufficiency", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Risk Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Shock, Septic", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "INSERM, U657 Pharmaco-Epid\u00e9miologie et Evaluation de l\u2019Impact des Produits de Sant\u00e9 sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France", 
              "id": "http://www.grid.ac/institutes/grid.412041.2", 
              "name": [
                "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
                "INSERM, U657 Pharmaco-Epid\u00e9miologie et Evaluation de l\u2019Impact des Produits de Sant\u00e9 sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Boyer", 
            "givenName": "Alexandre", 
            "id": "sg:person.01146613615.31", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146613615.31"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
              "id": "http://www.grid.ac/institutes/grid.42399.35", 
              "name": [
                "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gruson", 
            "givenName": "Didier", 
            "id": "sg:person.01053512353.85", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053512353.85"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "D\u00e9partement de Pharmacotoxicologie, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
              "id": "http://www.grid.ac/institutes/grid.42399.35", 
              "name": [
                "INSERM, U657 Pharmaco-Epid\u00e9miologie et Evaluation de l\u2019Impact des Produits de Sant\u00e9 sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France", 
                "D\u00e9partement de Pharmacotoxicologie, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bouchet", 
            "givenName": "St\u00e9phane", 
            "id": "sg:person.01264657231.76", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264657231.76"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
              "id": "http://www.grid.ac/institutes/grid.42399.35", 
              "name": [
                "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Clouzeau", 
            "givenName": "Benjamin", 
            "id": "sg:person.01306660172.66", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306660172.66"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
              "id": "http://www.grid.ac/institutes/grid.42399.35", 
              "name": [
                "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hoang-Nam", 
            "givenName": "Bui", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
              "id": "http://www.grid.ac/institutes/grid.42399.35", 
              "name": [
                "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vargas", 
            "givenName": "Fr\u00e9d\u00e9ric", 
            "id": "sg:person.01236106016.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236106016.48"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
              "id": "http://www.grid.ac/institutes/grid.42399.35", 
              "name": [
                "Service de R\u00e9animation M\u00e9dicale, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gilles", 
            "givenName": "Hilbert", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "D\u00e9partement de Pharmacotoxicologie, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
              "id": "http://www.grid.ac/institutes/grid.42399.35", 
              "name": [
                "INSERM, U657 Pharmaco-Epid\u00e9miologie et Evaluation de l\u2019Impact des Produits de Sant\u00e9 sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France", 
                "D\u00e9partement de Pharmacotoxicologie, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Molimard", 
            "givenName": "Mathieu", 
            "id": "sg:person.01022677075.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022677075.09"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "INSERM, U657 Pharmaco-Epid\u00e9miologie et Evaluation de l\u2019Impact des Produits de Sant\u00e9 sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France", 
              "id": "http://www.grid.ac/institutes/grid.412041.2", 
              "name": [
                "INSERM, U657 Pharmaco-Epid\u00e9miologie et Evaluation de l\u2019Impact des Produits de Sant\u00e9 sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Rogues", 
            "givenName": "Anne-Marie", 
            "id": "sg:person.0657465515.15", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657465515.15"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "D\u00e9partement de Pharmacotoxicologie, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France", 
              "id": "http://www.grid.ac/institutes/grid.42399.35", 
              "name": [
                "INSERM, U657 Pharmaco-Epid\u00e9miologie et Evaluation de l\u2019Impact des Produits de Sant\u00e9 sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France", 
                "D\u00e9partement de Pharmacotoxicologie, CHU de Bordeaux, 3 place Am\u00e9lie Raba-L\u00e9on, 33076, Bordeaux CEDEX, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Moore", 
            "givenName": "Nicholas", 
            "id": "sg:person.0656556671.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656556671.39"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00019053-199814040-00005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034928802", 
              "https://doi.org/10.2165/00019053-199814040-00005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01086153", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052176997", 
              "https://doi.org/10.1007/bf01086153"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-200342050-00007", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014607291", 
              "https://doi.org/10.2165/00003088-200342050-00007"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00271057", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004392772", 
              "https://doi.org/10.1007/bf00271057"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1046/j.1525-1497.1998.00224.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021701109", 
              "https://doi.org/10.1046/j.1525-1497.1998.00224.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01712162", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038871033", 
              "https://doi.org/10.1007/bf01712162"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01059684", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038719762", 
              "https://doi.org/10.1007/bf01059684"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-200038040-00005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011834186", 
              "https://doi.org/10.2165/00003088-200038040-00005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1016/s0009-9236(97)90156-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036698998", 
              "https://doi.org/10.1016/s0009-9236(97)90156-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00019053-199610050-00007", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014578471", 
              "https://doi.org/10.2165/00019053-199610050-00007"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00134-009-1530-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027367443", 
              "https://doi.org/10.1007/s00134-009-1530-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01706354", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050521465", 
              "https://doi.org/10.1007/bf01706354"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00134-002-1313-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1053202706", 
              "https://doi.org/10.1007/s00134-002-1313-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/cc2872", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031071552", 
              "https://doi.org/10.1186/cc2872"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1111/j.1572-0241.2001.03958.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1029109054", 
              "https://doi.org/10.1111/j.1572-0241.2001.03958.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-200140110-00002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009654086", 
              "https://doi.org/10.2165/00003088-200140110-00002"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00134-009-1635-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040333026", 
              "https://doi.org/10.1007/s00134-009-1635-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00002018-199716030-00005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042584490", 
              "https://doi.org/10.2165/00002018-199716030-00005"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2013-03-19", 
        "datePublishedReg": "2013-03-19", 
        "description": "Aminoglycoside nephrotoxicity has been reported in patients with sepsis, and several risk factors have been described. Once-daily dosing and shorter treatment have reduced nephrotoxicity risk, and simplified aminoglycoside monitoring. This review focuses on nephrotoxicity associated with aminoglycosides in the subset of patients with septic shock or severe sepsis. These patients are radically different from those with less severe sepsis. They may have, for instance, renal impairment due to the shock per se, sepsis-related acute kidney injury, frequent association with pre-existing risk factors for renal failure such as diabetes, dehydration and other nephrotoxic treatments. In this category of patients, these risk factors might modify substantially the benefit-risk ratio of aminoglycosides. In addition, aminoglycoside administration in critically ill patients with sepsis is complicated by an extreme inter- and intra-individual variability in drug pharmacokinetic/pharmacodynamic characteristics: the volume of distribution (Vd) is frequently increased while the elimination constant can be either increased or decreased. Consequently, and although its effect on nephrotoxicity has not been explored, a different administration schedule, i.e. a high-dose once daily (HDOD), and several therapeutic drug monitoring (TDM) options have been proposed in these patients. This review describes the historical perspective of these different options, including those applying to subsets of patients in which aminoglycoside administration is even more complex (obese intensive care unit [ICU] patients, patients needing continuous or discontinuous renal replacement therapy [CRRT/DRRT]). A simple linear dose adjustment according to aminoglycoside serum concentration can be classified as low-intensity TDM. Nomograms have also been proposed, based on the maximum (peak) plasma concentration (Cmax) objectives, weight and creatinine clearance. The Sawchuk and Zaske method (based on the determination of Cmax and an intermediate aminoglycoside assay before minimum plasma concentration) and the Bayesian method were both classified as high-intensity TDM programmes. Given the mean cost of aminoglycoside nephrotoxicity, these programmes may be cost-effective if its prevalence is above 10\u00a0%. However, none of these high-intensity TDM programmes have demonstrated a reduction of aminoglycoside-associated nephrotoxicity in patients with septic shock. Therefore, the questions remain as to, first, whether a TDM programme is relevant and, second, what intensity of TDM is achievable in the ICU, i.e. how it can be practically applied in the ICU setting where urgent care and high workload are substantial obstacles to a sophisticated, optimized aminoglycoside administration.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s40264-013-0031-0", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1096281", 
            "issn": [
              "0114-5916", 
              "1179-1942"
            ], 
            "name": "Drug Safety", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "4", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "36"
          }
        ], 
        "keywords": [
          "subset of patients", 
          "septic shock", 
          "aminoglycoside administration", 
          "risk factors", 
          "severe sepsis", 
          "aminoglycoside nephrotoxicity", 
          "sepsis-related acute kidney injury", 
          "pre-existing risk factors", 
          "aminoglycoside serum concentrations", 
          "aminoglycoside-associated nephrotoxicity", 
          "acute kidney injury", 
          "category of patients", 
          "benefit-risk ratio", 
          "volume of distribution", 
          "different administration schedules", 
          "TDM programs", 
          "aminoglycoside monitoring", 
          "renal impairment", 
          "kidney injury", 
          "creatinine clearance", 
          "renal failure", 
          "dose adjustment", 
          "nephrotoxicity risk", 
          "ill patients", 
          "administration schedule", 
          "pharmacodynamic characteristics", 
          "serum concentrations", 
          "nephrotoxic treatment", 
          "urgent care", 
          "Zaske method", 
          "mean cost", 
          "patients", 
          "sepsis", 
          "nephrotoxicity", 
          "frequent association", 
          "intra-individual variability", 
          "elimination constant", 
          "administration", 
          "aminoglycosides", 
          "ICU", 
          "short treatment", 
          "treatment", 
          "high workload", 
          "review", 
          "diabetes", 
          "options", 
          "dosing", 
          "injury", 
          "monitoring options", 
          "factors", 
          "prevalence", 
          "shock", 
          "nomogram", 
          "impairment", 
          "subset", 
          "clearance", 
          "care", 
          "drugs", 
          "risk", 
          "association", 
          "substantial obstacles", 
          "Sawchuk", 
          "program", 
          "failure", 
          "TDM", 
          "adjustment", 
          "schedule", 
          "weight", 
          "reduction", 
          "effect", 
          "volume", 
          "concentration", 
          "objective", 
          "monitoring", 
          "different options", 
          "categories", 
          "addition", 
          "inter", 
          "ratio", 
          "method", 
          "variability", 
          "workload", 
          "dehydration", 
          "characteristics", 
          "intensity", 
          "historical perspective", 
          "questions", 
          "obstacles", 
          "instances", 
          "perspective", 
          "cost", 
          "distribution", 
          "Bayesian methods", 
          "constants", 
          "extreme inter", 
          "therapeutic drug monitoring (TDM) options", 
          "drug monitoring (TDM) options", 
          "simple linear dose adjustment", 
          "linear dose adjustment", 
          "low-intensity TDM", 
          "maximum (peak) plasma concentration (Cmax) objectives", 
          "plasma concentration (Cmax) objectives", 
          "concentration (Cmax) objectives", 
          "high-intensity TDM programmes", 
          "intensity of TDM"
        ], 
        "name": "Aminoglycosides in Septic Shock", 
        "pagination": "217-230", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1010536097"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s40264-013-0031-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "23508544"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s40264-013-0031-0", 
          "https://app.dimensions.ai/details/publication/pub.1010536097"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:28", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_594.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s40264-013-0031-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40264-013-0031-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40264-013-0031-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40264-013-0031-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40264-013-0031-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    339 TRIPLES      22 PREDICATES      157 URIs      131 LITERALS      15 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s40264-013-0031-0 schema:about N1685007fa86d48e08f0357aec6821b68
    2 N4260e836ef934797aed787ea357dee28
    3 N454b3b1869c34b88be6d4e55f00700f3
    4 N6c127d1e198d48a5b2c68b8d42abf9d8
    5 N8861895f79b94c79bafb94a55568625e
    6 Naa2713385fbf481daae39361c05bfb6a
    7 Nc70ec73e16ab4f75b0c2ed805ff8154a
    8 Nf5cd992c359940b4ae954ffc0b40f543
    9 anzsrc-for:11
    10 anzsrc-for:1103
    11 schema:author N32b35744882444e28866952c88663637
    12 schema:citation sg:pub.10.1007/bf00271057
    13 sg:pub.10.1007/bf01059684
    14 sg:pub.10.1007/bf01086153
    15 sg:pub.10.1007/bf01706354
    16 sg:pub.10.1007/bf01712162
    17 sg:pub.10.1007/s00134-002-1313-7
    18 sg:pub.10.1007/s00134-009-1530-4
    19 sg:pub.10.1007/s00134-009-1635-9
    20 sg:pub.10.1016/s0009-9236(97)90156-9
    21 sg:pub.10.1046/j.1525-1497.1998.00224.x
    22 sg:pub.10.1111/j.1572-0241.2001.03958.x
    23 sg:pub.10.1186/cc2872
    24 sg:pub.10.2165/00002018-199716030-00005
    25 sg:pub.10.2165/00003088-200038040-00005
    26 sg:pub.10.2165/00003088-200140110-00002
    27 sg:pub.10.2165/00003088-200342050-00007
    28 sg:pub.10.2165/00019053-199610050-00007
    29 sg:pub.10.2165/00019053-199814040-00005
    30 schema:datePublished 2013-03-19
    31 schema:datePublishedReg 2013-03-19
    32 schema:description Aminoglycoside nephrotoxicity has been reported in patients with sepsis, and several risk factors have been described. Once-daily dosing and shorter treatment have reduced nephrotoxicity risk, and simplified aminoglycoside monitoring. This review focuses on nephrotoxicity associated with aminoglycosides in the subset of patients with septic shock or severe sepsis. These patients are radically different from those with less severe sepsis. They may have, for instance, renal impairment due to the shock per se, sepsis-related acute kidney injury, frequent association with pre-existing risk factors for renal failure such as diabetes, dehydration and other nephrotoxic treatments. In this category of patients, these risk factors might modify substantially the benefit-risk ratio of aminoglycosides. In addition, aminoglycoside administration in critically ill patients with sepsis is complicated by an extreme inter- and intra-individual variability in drug pharmacokinetic/pharmacodynamic characteristics: the volume of distribution (Vd) is frequently increased while the elimination constant can be either increased or decreased. Consequently, and although its effect on nephrotoxicity has not been explored, a different administration schedule, i.e. a high-dose once daily (HDOD), and several therapeutic drug monitoring (TDM) options have been proposed in these patients. This review describes the historical perspective of these different options, including those applying to subsets of patients in which aminoglycoside administration is even more complex (obese intensive care unit [ICU] patients, patients needing continuous or discontinuous renal replacement therapy [CRRT/DRRT]). A simple linear dose adjustment according to aminoglycoside serum concentration can be classified as low-intensity TDM. Nomograms have also been proposed, based on the maximum (peak) plasma concentration (Cmax) objectives, weight and creatinine clearance. The Sawchuk and Zaske method (based on the determination of Cmax and an intermediate aminoglycoside assay before minimum plasma concentration) and the Bayesian method were both classified as high-intensity TDM programmes. Given the mean cost of aminoglycoside nephrotoxicity, these programmes may be cost-effective if its prevalence is above 10 %. However, none of these high-intensity TDM programmes have demonstrated a reduction of aminoglycoside-associated nephrotoxicity in patients with septic shock. Therefore, the questions remain as to, first, whether a TDM programme is relevant and, second, what intensity of TDM is achievable in the ICU, i.e. how it can be practically applied in the ICU setting where urgent care and high workload are substantial obstacles to a sophisticated, optimized aminoglycoside administration.
    33 schema:genre article
    34 schema:inLanguage en
    35 schema:isAccessibleForFree false
    36 schema:isPartOf N683b3303752942b8bca06c10fc280037
    37 Nac39ff246d8a4780877ba4ef1593d86d
    38 sg:journal.1096281
    39 schema:keywords Bayesian methods
    40 ICU
    41 Sawchuk
    42 TDM
    43 TDM programs
    44 Zaske method
    45 acute kidney injury
    46 addition
    47 adjustment
    48 administration
    49 administration schedule
    50 aminoglycoside administration
    51 aminoglycoside monitoring
    52 aminoglycoside nephrotoxicity
    53 aminoglycoside serum concentrations
    54 aminoglycoside-associated nephrotoxicity
    55 aminoglycosides
    56 association
    57 benefit-risk ratio
    58 care
    59 categories
    60 category of patients
    61 characteristics
    62 clearance
    63 concentration
    64 concentration (Cmax) objectives
    65 constants
    66 cost
    67 creatinine clearance
    68 dehydration
    69 diabetes
    70 different administration schedules
    71 different options
    72 distribution
    73 dose adjustment
    74 dosing
    75 drug monitoring (TDM) options
    76 drugs
    77 effect
    78 elimination constant
    79 extreme inter
    80 factors
    81 failure
    82 frequent association
    83 high workload
    84 high-intensity TDM programmes
    85 historical perspective
    86 ill patients
    87 impairment
    88 injury
    89 instances
    90 intensity
    91 intensity of TDM
    92 inter
    93 intra-individual variability
    94 kidney injury
    95 linear dose adjustment
    96 low-intensity TDM
    97 maximum (peak) plasma concentration (Cmax) objectives
    98 mean cost
    99 method
    100 monitoring
    101 monitoring options
    102 nephrotoxic treatment
    103 nephrotoxicity
    104 nephrotoxicity risk
    105 nomogram
    106 objective
    107 obstacles
    108 options
    109 patients
    110 perspective
    111 pharmacodynamic characteristics
    112 plasma concentration (Cmax) objectives
    113 pre-existing risk factors
    114 prevalence
    115 program
    116 questions
    117 ratio
    118 reduction
    119 renal failure
    120 renal impairment
    121 review
    122 risk
    123 risk factors
    124 schedule
    125 sepsis
    126 sepsis-related acute kidney injury
    127 septic shock
    128 serum concentrations
    129 severe sepsis
    130 shock
    131 short treatment
    132 simple linear dose adjustment
    133 subset
    134 subset of patients
    135 substantial obstacles
    136 therapeutic drug monitoring (TDM) options
    137 treatment
    138 urgent care
    139 variability
    140 volume
    141 volume of distribution
    142 weight
    143 workload
    144 schema:name Aminoglycosides in Septic Shock
    145 schema:pagination 217-230
    146 schema:productId N8f61686946a64fca85dcdfb35f7105d5
    147 Nb28ee00612534a968bb20a3a5daea6db
    148 Nb93339263e70457bb4c1aa4778e91ca1
    149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010536097
    150 https://doi.org/10.1007/s40264-013-0031-0
    151 schema:sdDatePublished 2021-12-01T19:28
    152 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    153 schema:sdPublisher N156802f662204d9ea36f093d042a9759
    154 schema:url https://doi.org/10.1007/s40264-013-0031-0
    155 sgo:license sg:explorer/license/
    156 sgo:sdDataset articles
    157 rdf:type schema:ScholarlyArticle
    158 N156802f662204d9ea36f093d042a9759 schema:name Springer Nature - SN SciGraph project
    159 rdf:type schema:Organization
    160 N1685007fa86d48e08f0357aec6821b68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Kidney
    162 rdf:type schema:DefinedTerm
    163 N1bdf1b4bee5246ef84744f56b7956965 rdf:first sg:person.01236106016.48
    164 rdf:rest N96af4017f4774437a08bd61c8708d6fc
    165 N32b35744882444e28866952c88663637 rdf:first sg:person.01146613615.31
    166 rdf:rest N912e392f0dc645a7bb7a05b1e05c05a2
    167 N4260e836ef934797aed787ea357dee28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Renal Insufficiency
    169 rdf:type schema:DefinedTerm
    170 N454b3b1869c34b88be6d4e55f00700f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Anti-Bacterial Agents
    172 rdf:type schema:DefinedTerm
    173 N683b3303752942b8bca06c10fc280037 schema:issueNumber 4
    174 rdf:type schema:PublicationIssue
    175 N6c127d1e198d48a5b2c68b8d42abf9d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Shock, Septic
    177 rdf:type schema:DefinedTerm
    178 N8329cb3c99994519a403ca8463dce862 rdf:first sg:person.01306660172.66
    179 rdf:rest Nb5293237fe1f42e995bfcc27a1afb020
    180 N8861895f79b94c79bafb94a55568625e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Humans
    182 rdf:type schema:DefinedTerm
    183 N8f61686946a64fca85dcdfb35f7105d5 schema:name pubmed_id
    184 schema:value 23508544
    185 rdf:type schema:PropertyValue
    186 N912e392f0dc645a7bb7a05b1e05c05a2 rdf:first sg:person.01053512353.85
    187 rdf:rest Nab9ac08dbc19456ca9622a45f916d55b
    188 N96af4017f4774437a08bd61c8708d6fc rdf:first N9744f81b4720412983e1b773e52fc345
    189 rdf:rest Nc839660a5c084804b6cd080d733c2f2c
    190 N9744f81b4720412983e1b773e52fc345 schema:affiliation grid-institutes:grid.42399.35
    191 schema:familyName Gilles
    192 schema:givenName Hilbert
    193 rdf:type schema:Person
    194 N9af6125c99774e4db1d23549b844cedd rdf:first sg:person.0656556671.39
    195 rdf:rest rdf:nil
    196 Naa2713385fbf481daae39361c05bfb6a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    197 schema:name Risk Factors
    198 rdf:type schema:DefinedTerm
    199 Nab9ac08dbc19456ca9622a45f916d55b rdf:first sg:person.01264657231.76
    200 rdf:rest N8329cb3c99994519a403ca8463dce862
    201 Nac39ff246d8a4780877ba4ef1593d86d schema:volumeNumber 36
    202 rdf:type schema:PublicationVolume
    203 Nb28ee00612534a968bb20a3a5daea6db schema:name dimensions_id
    204 schema:value pub.1010536097
    205 rdf:type schema:PropertyValue
    206 Nb5293237fe1f42e995bfcc27a1afb020 rdf:first Nfd41db9811c1499bbb5255082b668d39
    207 rdf:rest N1bdf1b4bee5246ef84744f56b7956965
    208 Nb93339263e70457bb4c1aa4778e91ca1 schema:name doi
    209 schema:value 10.1007/s40264-013-0031-0
    210 rdf:type schema:PropertyValue
    211 Nc603394c57b24d91a2f30a519a8bc2f2 rdf:first sg:person.0657465515.15
    212 rdf:rest N9af6125c99774e4db1d23549b844cedd
    213 Nc70ec73e16ab4f75b0c2ed805ff8154a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    214 schema:name Drug Monitoring
    215 rdf:type schema:DefinedTerm
    216 Nc839660a5c084804b6cd080d733c2f2c rdf:first sg:person.01022677075.09
    217 rdf:rest Nc603394c57b24d91a2f30a519a8bc2f2
    218 Nf5cd992c359940b4ae954ffc0b40f543 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    219 schema:name Aminoglycosides
    220 rdf:type schema:DefinedTerm
    221 Nfd41db9811c1499bbb5255082b668d39 schema:affiliation grid-institutes:grid.42399.35
    222 schema:familyName Hoang-Nam
    223 schema:givenName Bui
    224 rdf:type schema:Person
    225 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    226 schema:name Medical and Health Sciences
    227 rdf:type schema:DefinedTerm
    228 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    229 schema:name Clinical Sciences
    230 rdf:type schema:DefinedTerm
    231 sg:journal.1096281 schema:issn 0114-5916
    232 1179-1942
    233 schema:name Drug Safety
    234 schema:publisher Springer Nature
    235 rdf:type schema:Periodical
    236 sg:person.01022677075.09 schema:affiliation grid-institutes:grid.42399.35
    237 schema:familyName Molimard
    238 schema:givenName Mathieu
    239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022677075.09
    240 rdf:type schema:Person
    241 sg:person.01053512353.85 schema:affiliation grid-institutes:grid.42399.35
    242 schema:familyName Gruson
    243 schema:givenName Didier
    244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053512353.85
    245 rdf:type schema:Person
    246 sg:person.01146613615.31 schema:affiliation grid-institutes:grid.412041.2
    247 schema:familyName Boyer
    248 schema:givenName Alexandre
    249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146613615.31
    250 rdf:type schema:Person
    251 sg:person.01236106016.48 schema:affiliation grid-institutes:grid.42399.35
    252 schema:familyName Vargas
    253 schema:givenName Frédéric
    254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236106016.48
    255 rdf:type schema:Person
    256 sg:person.01264657231.76 schema:affiliation grid-institutes:grid.42399.35
    257 schema:familyName Bouchet
    258 schema:givenName Stéphane
    259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264657231.76
    260 rdf:type schema:Person
    261 sg:person.01306660172.66 schema:affiliation grid-institutes:grid.42399.35
    262 schema:familyName Clouzeau
    263 schema:givenName Benjamin
    264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306660172.66
    265 rdf:type schema:Person
    266 sg:person.0656556671.39 schema:affiliation grid-institutes:grid.42399.35
    267 schema:familyName Moore
    268 schema:givenName Nicholas
    269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656556671.39
    270 rdf:type schema:Person
    271 sg:person.0657465515.15 schema:affiliation grid-institutes:grid.412041.2
    272 schema:familyName Rogues
    273 schema:givenName Anne-Marie
    274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0657465515.15
    275 rdf:type schema:Person
    276 sg:pub.10.1007/bf00271057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004392772
    277 https://doi.org/10.1007/bf00271057
    278 rdf:type schema:CreativeWork
    279 sg:pub.10.1007/bf01059684 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038719762
    280 https://doi.org/10.1007/bf01059684
    281 rdf:type schema:CreativeWork
    282 sg:pub.10.1007/bf01086153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052176997
    283 https://doi.org/10.1007/bf01086153
    284 rdf:type schema:CreativeWork
    285 sg:pub.10.1007/bf01706354 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050521465
    286 https://doi.org/10.1007/bf01706354
    287 rdf:type schema:CreativeWork
    288 sg:pub.10.1007/bf01712162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038871033
    289 https://doi.org/10.1007/bf01712162
    290 rdf:type schema:CreativeWork
    291 sg:pub.10.1007/s00134-002-1313-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053202706
    292 https://doi.org/10.1007/s00134-002-1313-7
    293 rdf:type schema:CreativeWork
    294 sg:pub.10.1007/s00134-009-1530-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027367443
    295 https://doi.org/10.1007/s00134-009-1530-4
    296 rdf:type schema:CreativeWork
    297 sg:pub.10.1007/s00134-009-1635-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040333026
    298 https://doi.org/10.1007/s00134-009-1635-9
    299 rdf:type schema:CreativeWork
    300 sg:pub.10.1016/s0009-9236(97)90156-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036698998
    301 https://doi.org/10.1016/s0009-9236(97)90156-9
    302 rdf:type schema:CreativeWork
    303 sg:pub.10.1046/j.1525-1497.1998.00224.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1021701109
    304 https://doi.org/10.1046/j.1525-1497.1998.00224.x
    305 rdf:type schema:CreativeWork
    306 sg:pub.10.1111/j.1572-0241.2001.03958.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1029109054
    307 https://doi.org/10.1111/j.1572-0241.2001.03958.x
    308 rdf:type schema:CreativeWork
    309 sg:pub.10.1186/cc2872 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031071552
    310 https://doi.org/10.1186/cc2872
    311 rdf:type schema:CreativeWork
    312 sg:pub.10.2165/00002018-199716030-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042584490
    313 https://doi.org/10.2165/00002018-199716030-00005
    314 rdf:type schema:CreativeWork
    315 sg:pub.10.2165/00003088-200038040-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011834186
    316 https://doi.org/10.2165/00003088-200038040-00005
    317 rdf:type schema:CreativeWork
    318 sg:pub.10.2165/00003088-200140110-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009654086
    319 https://doi.org/10.2165/00003088-200140110-00002
    320 rdf:type schema:CreativeWork
    321 sg:pub.10.2165/00003088-200342050-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014607291
    322 https://doi.org/10.2165/00003088-200342050-00007
    323 rdf:type schema:CreativeWork
    324 sg:pub.10.2165/00019053-199610050-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014578471
    325 https://doi.org/10.2165/00019053-199610050-00007
    326 rdf:type schema:CreativeWork
    327 sg:pub.10.2165/00019053-199814040-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034928802
    328 https://doi.org/10.2165/00019053-199814040-00005
    329 rdf:type schema:CreativeWork
    330 grid-institutes:grid.412041.2 schema:alternateName INSERM, U657 Pharmaco-Epidémiologie et Evaluation de l’Impact des Produits de Santé sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France
    331 schema:name INSERM, U657 Pharmaco-Epidémiologie et Evaluation de l’Impact des Produits de Santé sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France
    332 Service de Réanimation Médicale, CHU de Bordeaux, 3 place Amélie Raba-Léon, 33076, Bordeaux CEDEX, France
    333 rdf:type schema:Organization
    334 grid-institutes:grid.42399.35 schema:alternateName Département de Pharmacotoxicologie, CHU de Bordeaux, 3 place Amélie Raba-Léon, 33076, Bordeaux CEDEX, France
    335 Service de Réanimation Médicale, CHU de Bordeaux, 3 place Amélie Raba-Léon, 33076, Bordeaux CEDEX, France
    336 schema:name Département de Pharmacotoxicologie, CHU de Bordeaux, 3 place Amélie Raba-Léon, 33076, Bordeaux CEDEX, France
    337 INSERM, U657 Pharmaco-Epidémiologie et Evaluation de l’Impact des Produits de Santé sur les Populations, Univ. de Bordeaux, U 657, 33000, Bordeaux, France
    338 Service de Réanimation Médicale, CHU de Bordeaux, 3 place Amélie Raba-Léon, 33076, Bordeaux CEDEX, France
    339 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...